Abstract

Drug delivery is evolving at a rapid rate with new drug product formulations
being discovered frequently. Advanced drug delivery deals with developing
solutions for new entities in therapeutic pharmacology such as protein and
peptides and other novel compounds targeting drugs to specific disease sites
including gene therapy. Treatments for chronic conditions and growth in
patient-administered drugs are factors leading to greater focus on ease-of-use
and convenience. Advanced Drug Delivery Markets (Liposomes, Polymers and
Monoclonal Antibodies) details the types of drug delivery systems,
technologies and products utilizing advanced drug delivery systems The report
describes the industry, its relationship to various healthcare channels, and
the trends for the future.

The advanced drug delivery market is two-fold. First of all it identifies drug
delivery technology Secondly, it identifies products in the pharmaceutical
arena that utilize those drug delivery technologies. Because drug delivery
technology is an integral part of sales of pharmaceuticals and drug delivery
technology cannot exist without pharmaceuticals, revenues have been reported
that include pharmaceutical sales. This report will provide market data that
includes the pharmaceutical revenues of those products that utilize advanced
drug delivery.

In this report, the advanced drug delivery market is divided into three main
segments and market estimates are provided for indications within each
category:

The following types of polymer delivery drugs are segmented within this report.

PEGylated Delivery

Emulsuion Delivery

Injectable Delivery

Nanoparticle Delivery

Others

A wide range of trends and issues that will impact the advance drug delivery
market are discussed in the report including the current state of biotechnolgy
expansion, molecular imprinted polymers, hot-melt extrusion,
metallofullerenes, nanotechnology advancements and other emerging Drug
Delivery technologies not yet on the market.

The following companies are profiled in the report:

Alkermes, Inc.

ALZA Corporation

AP Pharma

Centocor Ortho Biotech, Inc.

Eisai , Inc

Elan Corporation, Plc

EnColl Corporation, Inc.

Enzon Pharmaceuticals, Inc

Gilead Sciences, Inc.

Nektar Therapeutics

PDL BioPharma

pSivida Corp

SurModics, Inc

Tolmar, Inc

The research conducted by Kalorama Information included comprehensive research
of primary and secondary sources such as interviews with company executives,
company literature, databases, investment reports, and medical and business
journals. New technologies, market developments, and research and development
trends and expenditures were identified through patent and data-based
searches, as well as via interviews with key personnel. Person-to-person and
telephone interviews were the primary method of gathering information. E-mail
correspondence was also used in the interview process. Interviews with 24 key
industry officials, trade association spokespersons, consultants, healthcare
providers, and government personnel were compiled to form the primary basis of
information - particularly revenue and market share data- presented in this
report.

All market data pertains to the worldwide market at the manufacturers' level
and was measured in U.S. dollars. The base year for data was 2010. Historical
data are provided for 2006 through 2009, with forecast data provided for 2010
through 2014. Compound annual growth rates (CAGR) are provided for the
2006-2010, 2010-2014 and 2006-2014.